Oncology API
Oncology API are active pharmaceutical ingredients (APIs) that are used to treat various forms of cancer. They are the biologically active substances that deliver the intended anticancer therapeutic effects.
- Alkylating agent
- ALK/ROS1 inhibitor
- Androgen biosynthesis inhibitor
- BCL-2 inhibitor
- BRAF inhibitor
- BTK inhibitor
- CDK inhibitor
- Cytidine deaminase inhibitor
- EGFR inhibitor
- EZH2 inhibitor
- FGFR inhibitor
- Gamma-secretase inhibitor
- GnRH receptor antagonist
- HDAC Inhibitors
- IDH1 inhibitor
- JAK inhibitor
- Kinase inhibitor
- MEK inhibitor
- MET tyrosine kinase inhibitor
- Mitogen-activated protein kinase inhibitor
- Multikinase inhibitor
- NaV1.8 inhibitor
- Nonsteroidal AR inhibitor
- Pan-AKT kinase inhibitor
- PARP inhibitor
- Proteasome inhibitor
- PSMA inhibitor
- RAF inhibitor
- RET kinase inhibitor
- SAA1 Inhibitors
- SINE
- Smo antagonist
- Tyrosine kinase inhibitor
| Catalog | Product Name | Structure | M.W. | Purity | Pricing |
|---|---|---|---|---|---|
| Alkylating agent | |||||
| BP-43617 | Treosulfan |  | 278.3 | Pricing | |
| BP-44029 | Melphalan flufenamide hydrochloride |  | 498.4 | Pricing | |
| ALK/ROS1 inhibitor | |||||
| BP-44027 | Lorlatinib |  | 406.4 | Pricing | |
| Androgen biosynthesis inhibitor | |||||
| BP-43622 | Abiraterone Acetate |  | 391.6 | Pricing | |
| BCL-2 inhibitor | |||||
| BP-43649 | Venetoclax (ABT-199) |  | 868.5 | Pricing | |
| BRAF inhibitor | |||||
| BP-44063 | Vemurafenib |  | 489.9 | Pricing | |
| BTK inhibitor | |||||
| BP-44065 | Zanubrutinib |  | 471.6 | Pricing | |
| CDK inhibitor | |||||
| BP-44045 | Ribociclib |  | 434.5 | Pricing | |
| BP-44037 | Palbociclib |  | 447.5 | Pricing | |
| BP-43646 | Ribociclib Succinate |  | 552.6 | Pricing | |
| Cytidine deaminase inhibitor | |||||
| BP-43639 | Cedazuridine |  | 268.2 | Pricing | |
| EGFR inhibitor | |||||
| BP-43658 | Lazertinib |  | 554.7 | Pricing | |
| BP-44032 | Neratinib |  | 557.1 | Pricing | |
| EZH2 inhibitor | |||||
| BP-44055 | Tazemetostat |  | 572.8 | Pricing | |
| FGFR inhibitor | |||||
| BP-43657 | Infigratinib |  | 560.5 | Pricing | |
| Gamma-secretase inhibitor | |||||
| BP-44035 | Nirogacestat dihydrobromide |  | 489.7 | Pricing | |
| GnRH receptor antagonist | |||||
| BP-44043 | Relugolix |  | 623.6 | Pricing | |
| BP-43648 | Elagolix Sodium |  | 653.6 | Pricing | |
| BP-44060 | Triptorelin |  | 1311.5 | Pricing | |
| HDAC Inhibitors | |||||
| BP-40062 | 4SC-202 |  | 447.5 | Pricing | |
| BP-40065 | Belinostat |  | 318.4 | Pricing | |
| BP-40066 | CUDC-101 |  | 434.5 | Pricing | |
| BP-40072 | Quisinostat HCl |  | 394.5 | Pricing | |
| BP-40067 | Dacinostat |  | 379.5 | Pricing | |
| BP-40063 | Abexinostat |  | 397.4 | Pricing | |
| BP-40077 | Tubastatin A |  | 335.4 | Pricing | |
| BP-40068 | Fimepinostat |  | 508.6 | Pricing | |
| BP-40073 | Rocilinostat |  | 433.5 | Pricing | |
| BP-40069 | LMK-235 |  | 294.4 | Pricing | |
| BP-40070 | Mocetinostat |  | 396.5 | Pricing | |
| BP-40071 | Pracinostat |  | 358.5 | Pricing | |
| BP-40074 | Romidepsin |  | 540.7 | Pricing | |
| BP-40075 | Splitomicin |  | 198.2 | Pricing | |
| BP-40076 | TMP269 |  | 514.5 | Pricing | |
| BP-40078 | Voruciclib |  | 469.8 | Pricing | |
| BP-40079 | Chidamide |  | 390.4 | Pricing | |
| IDH1 inhibitor | |||||
| BP-44036 | Olutasidenib |  | 354.8 | Pricing | |
| BP-44064 | Vorasidenib |  | 414.7 | Pricing | |
| BP-43660 | Ivosidenib |  | 583 | Pricing | |
| JAK inhibitor | |||||
| BP-44053 | Ritlecitinib |  | 285.4 | Pricing | |
| BP-44052 | Ruxolitinib |  | 306.4 | Pricing | |
| Kinase inhibitor | |||||
| BP-43656 | Inavolisib |  | 407.4 | Pricing | |
| BP-43640 | Duvelisib |  | 416.9 | Pricing | |
| BP-43643 | Ibrutinib |  | 440.5 | Pricing | |
| BP-43628 | Binimetinib |  | 441.2 | Pricing | |
| BP-43645 | Palbociclib Hydrochloride |  | 447.5 | Pricing | |
| BP-43623 | Acalabrutinib |  | 465.5 | Pricing | |
| BP-43638 | Dacomitinib |  | 470 | Pricing | |
| BP-43653 | Pirtobrutinib |  | 479.4 | Pricing | |
| BP-43635 | Copanlisib |  | 480.5 | Pricing | |
| BP-44039 | Pemigatinib |  | 487.5 | Pricing | |
| BP-43621 | Abemaciclib |  | 506.6 | Pricing | |
| BP-43637 | Dabrafenib |  | 519.6 | Pricing | |
| BP-43634 | Cobimetinib |  | 531.3 | Pricing | |
| BP-44040 | Pralsetinib |  | 533.6 | Pricing | |
| BP-44041 | Quizartinib |  | 560.7 | Pricing | |
| BP-43624 | Adagrasib |  | 604.1 | Pricing | |
| MEK inhibitor | |||||
| BP-44059 | Trametinib |  | 615.4 | Pricing | |
| MET tyrosine kinase inhibitor | |||||
| BP-44056 | Tepotinib |  | 492.6 | Pricing | |
| Mitogen-activated protein kinase inhibitor | |||||
| BP-43620 | Mirdametinib |  | 482.2 | Pricing | |
| Multikinase inhibitor | |||||
| BP-44051 | Sorafenib |  | 464.8 | Pricing | |
| BP-44042 | Regorafenib |  | 482.8 | Pricing | |
| BP-44061 | Umbralisib |  | 571.6 | Pricing | |
| NaV1.8 inhibitor | |||||
| BP-43619 | Suzetrigine |  | 473.4 | Pricing | |
| Nonsteroidal AR inhibitor | |||||
| BP-43625 | Apalutamide (Amorphous & Form B) |  | 477.4 | Pricing | |
| Pan-AKT kinase inhibitor | |||||
| BP-43630 | Capivasertib |  | 428.9 | Pricing | |
| PARP inhibitor | |||||
| BP-44033 | Niraparib |  | 320.4 | Pricing | |
| BP-44047 | Rucaparib |  | 323.4 | Pricing | |
| BP-44054 | Talazoparib |  | 380.4 | Pricing | |
| BP-43641 | Olaparib |  | 434.5 | Pricing | |
| Proteasome inhibitor | |||||
| BP-43632 | Carfilzomib |  | 719.9 | Pricing | |
| BP-43659 | Ixazomib |  | 361 | Pricing | |
| PSMA inhibitor | |||||
| BP-44028 | Vipivotide tetraxetan |  | 1042.2 | Pricing | |
| RAF inhibitor | |||||
| BP-44058 | Tovorafenib |  | 506.3 | Pricing | |
| RET kinase inhibitor | |||||
| BP-44049 | Selpercatinib |  | 525.6 | Pricing | |
| SAA1 Inhibitors | |||||
| BP-43615 | SGA360 |  | 362.4 | Pricing | |
| SINE | |||||
| BP-44048 | Selinexor |  | 443.3 | Pricing | |
| Smo antagonist | |||||
| BP-44050 | Sonidegib |  | 485.5 | Pricing | |
| Tyrosine kinase inhibitor | |||||
| BP-44044 | Repotrectinib |  | 355.4 | Pricing | |
| BP-43627 | Axitinib |  | 386.5 | Pricing | |
| BP-43654 | Erlotinib |  | 393.4 | Pricing | |
| BP-43650 | Fruquintinib |  | 393.4 | Pricing | |
| BP-43631 | Capmatinib |  | 412.4 | Pricing | |
| BP-43663 | Lenvatinib |  | 426.9 | Pricing | |
| BP-43662 | Larotrectinib |  | 428.4 | Pricing | |
| BP-44038 | Pazopanib |  | 437.5 | Pricing | |
| BP-43636 | (R)-Crizotinib |  | 450.3 | Pricing | |
| BP-44057 | Tivozanib |  | 454.9 | Pricing | |
| BP-44062 | Vandetanib |  | 475.4 | Pricing | |
| BP-43626 | Afatinib |  | 485.9 | Pricing | |
| BP-43647 | Osimertinib Mesylate |  | 499.6 | Pricing | |
| BP-43629 | Cabozantinib |  | 501.5 | Pricing | |
| BP-44046 | Ripretinib |  | 510.4 | Pricing | |
| BP-43644 | Sunitinib Malate |  | 532.6 | Pricing | |
| BP-44034 | Nintedanib |  | 539.6 | Pricing | |
| BP-43655 | Gilteritinib |  | 552.7 | Pricing | |
| BP-43633 | Ceritinib |  | 558.1 | Pricing | |
| BP-43651 | Entrectinib |  | 560.7 | Pricing | |
| BP-43642 | Sotorasib |  | 560.6 | Pricing | |
| BP-44030 | Midostaurin |  | 570.7 | Pricing | |
| BP-43661 | Lapatinib |  | 581.1 | Pricing | |
| BP-44031 | Mobocertinib |  | 585.7 | Pricing | |